Author/Authors :
Van der Veldt، نويسنده , , Astrid A.M. and Lubberink، نويسنده , , Mark and Bahce، نويسنده , , Idris and Walraven، نويسنده , , Maudy and de Boer، نويسنده , , Michiel P. and Greuter، نويسنده , , Henri N.J.M. and Hendrikse، نويسنده , , N. Harry and Eriksson، نويسنده , , Jonas and Windhorst، نويسنده , , Albert D. and Postmus، نويسنده , , Pieter E. and Verheul، نويسنده , , Henk M. and Serné، نويسنده , , Erik H. and Lammertsma، نويسنده , , Adriaan A. and Smit، نويسنده , , Egbert F.، نويسنده ,
Abstract :
Summary
t strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([11C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [11C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.
